<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0">
  <channel>
    <title>Featured Headlines Feed for CYTK</title>
    <link />
    <description>Headlines for Cytokinetics, Inc.</description>
    <docs>http://www.rssboard.org/rss-specification</docs>
    <generator>Argotic Syndication Framework 2008.0.2.0, http://www.codeplex.com/Argotic</generator>
    <item>
      <title>Cytokinetics' CEO Hosts the Annual Meeting of Stockholders Conference (Transcript)</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1455691-cytokinetics-ceo-hosts-the-annual-meeting-of-stockholders-conference-transcript.aspx?source=itxwebtxt0000015</link>
      <author>Seeking Alpha</author>
      <pubDate>Thu, 23 May 2013 00:16:07 GMT</pubDate>
    </item>
    <item>
      <title>Cytokinetics' CEO Discusses Q1 2013 Results - Earnings Call Transcript</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1386791-cytokinetics-ceo-discusses-q1-2013-results-earnings-call-transcript.aspx?source=itxwebtxt0000015</link>
      <author>Seeking Alpha</author>
      <pubDate>Tue, 30 Apr 2013 18:43:05 GMT</pubDate>
    </item>
    <item>
      <title>5 Stocks Poised for Breakouts</title>
      <link>http://www.fool.com/news/xt/thestreet/www.stockpickr.com/5-stocks-poised-breakouts.html-30.aspx?puc=aol&amp;cm_ven=aol&amp;source=itxwebtxt0000015</link>
      <author>TheStreet</author>
      <pubDate>Fri, 19 Apr 2013 14:13:00 GMT</pubDate>
    </item>
    <item>
      <title>2 High Risk Biotech Stocks Under $2 That Could Yield A High Reward</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1347731-2-high-risk-biotech-stocks-under-2-that-could-yield-a-high-reward.aspx?source=itxwebtxt0000015</link>
      <author>Seeking Alpha</author>
      <pubDate>Wed, 17 Apr 2013 10:48:13 GMT</pubDate>
    </item>
    <item>
      <title>Cytokinetics: Key Issues For Beginning Phase III For Omecamtiv Mecarbil In Congestive Heart Failure</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1335271-cytokinetics-key-issues-for-beginning-phase-iii-for-omecamtiv-mecarbil-in-congestive-heart-failure.aspx?source=itxwebtxt0000015</link>
      <author>Seeking Alpha</author>
      <pubDate>Thu, 11 Apr 2013 13:14:59 GMT</pubDate>
    </item>
    <item>
      <title>Patients Dosed in Arena Study - Analyst Blog</title>
      <link>http://www.fool.com/news/xt/zacks/www.zacks.com/stock/news/96671/patients-dosed-in-arena-study.aspx?source=itxwebtxt0000015</link>
      <author>Zacks</author>
      <pubDate>Tue, 09 Apr 2013 17:55:01 GMT</pubDate>
    </item>
    <item>
      <title>AZN Reports Data on Fostamatinib - Analyst Blog</title>
      <link>http://www.fool.com/news/xt/zacks/www.zacks.com/stock/news/96563/azn-reports-data-on-fostamatinib.aspx?source=itxwebtxt0000015</link>
      <author>Zacks</author>
      <pubDate>Mon, 08 Apr 2013 18:35:01 GMT</pubDate>
    </item>
    <item>
      <title>Data Presented on Bayer's ATX-101 - Analyst Blog</title>
      <link>http://www.fool.com/news/xt/zacks/www.zacks.com/stock/news/96546/data-presented-on-bayers-atx-101.aspx?source=itxwebtxt0000015</link>
      <author>Zacks</author>
      <pubDate>Mon, 08 Apr 2013 17:30:01 GMT</pubDate>
    </item>
    <item>
      <title>Cytokinetics Begins CK-2127107 Study - Analyst Blog</title>
      <link>http://www.fool.com/news/xt/zacks/www.zacks.com/stock/news/96436/cytokinetics-begins-ck-2127107-study.aspx?source=itxwebtxt0000015</link>
      <author>Zacks</author>
      <pubDate>Fri, 05 Apr 2013 17:00:01 GMT</pubDate>
    </item>
    <item>
      <title>GHDX to Show Prostate Test Result - Analyst Blog</title>
      <link>http://www.fool.com/news/xt/zacks/www.zacks.com/stock/news/96425/ghdx-to-show-prostate-test-result.aspx?source=itxwebtxt0000015</link>
      <author>Zacks</author>
      <pubDate>Fri, 05 Apr 2013 16:15:01 GMT</pubDate>
    </item>
    <item>
      <title>Elan Gets Takeover Clarity - Analyst Blog</title>
      <link>http://www.fool.com/news/xt/zacks/www.zacks.com/stock/news/96348/elan-gets-takeover-clarity.aspx?source=itxwebtxt0000015</link>
      <author>Zacks</author>
      <pubDate>Thu, 04 Apr 2013 18:20:01 GMT</pubDate>
    </item>
    <item>
      <title>AstraZeneca Takes Over AlphaCore  - Analyst Blog</title>
      <link>http://www.fool.com/news/xt/zacks/www.zacks.com/stock/news/96333/astrazeneca-takes-over-alphacore.aspx?source=itxwebtxt0000015</link>
      <author>Zacks</author>
      <pubDate>Thu, 04 Apr 2013 16:40:01 GMT</pubDate>
    </item>
    <item>
      <title>ARNA/Eisai's Belviq Filed in Mexico - Analyst Blog</title>
      <link>http://www.fool.com/news/xt/zacks/www.zacks.com/stock/news/96226/arna-eisais-belviq-filed-in-mexico.aspx?source=itxwebtxt0000015</link>
      <author>Zacks</author>
      <pubDate>Wed, 03 Apr 2013 16:00:01 GMT</pubDate>
    </item>
    <item>
      <title>Elan Sells Off Tysabri Stake - Analyst Blog</title>
      <link>http://www.fool.com/news/xt/zacks/www.zacks.com/stock/news/96209/elan-sells-off-tysabri-stake.aspx?source=itxwebtxt0000015</link>
      <author>Zacks</author>
      <pubDate>Wed, 03 Apr 2013 13:54:01 GMT</pubDate>
    </item>
    <item>
      <title>Vivus Opts for Royalty Financing - Analyst Blog</title>
      <link>http://www.fool.com/news/xt/zacks/www.zacks.com/stock/news/96135/vivus-opts-for-royalty-financing.aspx?source=itxwebtxt0000015</link>
      <author>Zacks</author>
      <pubDate>Tue, 02 Apr 2013 18:38:01 GMT</pubDate>
    </item>
    <item>
      <title>Isis Publishes Encouraging Data - Analyst Blog</title>
      <link>http://www.fool.com/news/xt/zacks/www.zacks.com/stock/news/96104/isis-publishes-encouraging-data.aspx?source=itxwebtxt0000015</link>
      <author>Zacks</author>
      <pubDate>Tue, 02 Apr 2013 16:30:01 GMT</pubDate>
    </item>
    <item>
      <title>Cytokinetics Growth-By-Partnership Strategy Looks Viable When It Comes To CK-2127107</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1313761-cytokinetics-growth-by-partnership-strategy-looks-viable-when-it-comes-to-ck-2127107.aspx?source=itxwebtxt0000015</link>
      <author>Seeking Alpha</author>
      <pubDate>Tue, 02 Apr 2013 03:27:32 GMT</pubDate>
    </item>
    <item>
      <title>ANTH's Blisibimod Enters Phase III - Analyst Blog</title>
      <link>http://www.fool.com/news/xt/zacks/www.zacks.com/stock/news/96029/anths-blisibimod-enters-phase-iii.aspx?source=itxwebtxt0000015</link>
      <author>Zacks</author>
      <pubDate>Mon, 01 Apr 2013 18:35:01 GMT</pubDate>
    </item>
    <item>
      <title>Gilead's HCV Study to Continue - Analyst Blog</title>
      <link>http://www.fool.com/news/xt/zacks/www.zacks.com/stock/news/95997/gileads-hcv-study-to-continue.aspx?source=itxwebtxt0000015</link>
      <author>Zacks</author>
      <pubDate>Mon, 01 Apr 2013 16:05:01 GMT</pubDate>
    </item>
    <item>
      <title>Omeros Progresses with OMS824 - Analyst Blog</title>
      <link>http://www.fool.com/news/xt/zacks/www.zacks.com/stock/news/95907/omeros-progresses-with-oms824.aspx?source=itxwebtxt0000015</link>
      <author>Zacks</author>
      <pubDate>Thu, 28 Mar 2013 18:40:01 GMT</pubDate>
    </item>
  </channel>
</rss>
